There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report), LAVA Therapeutics (LVTX – Research Report) and Ocugen (OCGN – Research Report) with bullish sentiments.
Apellis Pharmaceuticals (APLS)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $82.00. The company’s shares closed last Tuesday at $30.76, close to its 52-week low of $19.83.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apellis Pharmaceuticals with a $73.23 average price target, implying a 135.0% upside from current levels. In a report issued on August 11, Robert W. Baird also maintained a Buy rating on the stock with a $70.00 price target.
See the top stocks recommended by analysts >>
LAVA Therapeutics (LVTX)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on LAVA Therapeutics today and set a price target of $6.00. The company’s shares closed last Tuesday at $1.83, close to its 52-week low of $1.37.
According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
LAVA Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.00, a 278.4% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $6.00 price target.
Ocugen (OCGN)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen, with a price target of $5.00. The company’s shares closed last Tuesday at $0.40.
According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocugen with a $5.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APLS:
- Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Stifel believes GA market is large enough for Apellis’ Syfovre
- Astellas Pharma announces FDA approval of Izervay for GA
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
